Antitumor effect of substituted quinolines in breast cancer cells

Drug Development Research

Volumn 69, Issue 8, 2008, Pages 526-534

  Gakhar, Gunjan ^a   Ohira, Takahiro ^a   Shi, Aibin ^a   Hua, Duy H ^a   Nguyen, Thu Annelise ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Connexins; Gap junctional intercellular communication; Quinolines

Indexed keywords

CASPASE 3; CONNEXIN 43; PQ 1; QUINOLINE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL COMMUNICATION; CELL VIABILITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; GAP JUNCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR XENOGRAFT;

EID: 58449126371     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20281     Document Type: Article

References (47)

1. Acevedo P, Bertram JS. 1995. Liarozole potentiates the cancer chemopreventive activity of and the upregulation of gap junctional communication and connexin43 expression by retinoic acid and beta-carotene in 10T1/2 cells. Carcinogenesis 16:2215-2222.
2. Ammerpohl O, Thormeyer D, Khan Z, Appelskog IB, Gojkovic Z, Almqvist PM, Ekstrom TJ. 2004. HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. Biochem Biophys Res Commun 324:8-14.
3. Bhimani RS, Troll W, Grunberger D, Frenkel K. 1993. Inhibition of oxidative stress in HeLa cells by chemopreventive agents. Cancer Res 53:4528-4533.
4. Boyle RG, Travers, S. 2006. Hypoxia: targeting the tumor. Anticancer Agents Med Chem 6:281-286.
5. Bruzzone R, White TW, Paul DL. 1996. Connections with connexins: the molecular basis of direct intercellular signaling. Eur J Biochem 238:1-27.
6. Clark PE, Hall MC, Borden Jr LS, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino Jr R, Lovato J, Harmon M, Torti FM. 2006. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 67:1257-1261.
7. Cnubben NHP, Wortelboer HM, van Zanden JJ, Rietjens VMCM, van Bladeren PJ. 2005. Metabolism of ATP-binding cassette drug transporter inhibitors: complicating factor for multidrug resistance. Expert Opin Drug Metab Toxicol 1:219-232.
8. Dubina MV, Iatckii NA, Popov DE, Vasil'ev SV, Krutovskikh VA. 2002. Connexin 43, but not connexin 32, is mutated at advanced stages of human sporadic colon cancer. Oncogene 21:4992-4996.
9. Eghbali B, Kessler JA, Reid LM, Roy C, Spray DC. 1991. Involvement of gap junctions in tumorigenesis: transfection of tumor cells with connexin 32 cDNA retards growth in vivo. Proc Natl Acad Sci USA 88:10701-10705.
10. Fleishman SJ, Unger VM, Ben-Tal N. 2006. Transmembrane protein structures without X-rays. Trends Biochem Sci 31:106-113.
11. Foote CI, Zhou L, Zhu X, Nicholson BJ. 1998. The pattern of disulfide linkages in the extracellular loop regions of connexin 32 suggests a model for the docking interface of gap junctions. J Cell Biol 140:1187-1197.
12. Goldberg GS, Martyn KD, Lau AF. 1994. A connexin 43 antisense vector reduces the ability of normal cells to inhibit the foci formation of transformed cells. Mol Carcinog 11:106-114.
13. Goodsell DS, Olson AJ. 1990. Automated docking of substrates to proteins by simulated annealing. Proteins 8:195-202.
14. Holder JW, Elmore E, Barrett JC. 1993. Gap junction function and cancer. Cancer Res 53:3475-3485.
15. Huang RP, Hossain MZ, Huang R, Gano J, Fan Y, Boynton AL. 2001. Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells. Int J Cancer 92:130-138.
16. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics, 2007. CA Cancer J Clin 57:43-66.
17. Kawase M, Motohashi N. 2003. New multidrug resistance reversal agents. Curr Drug Targets 4:31-43.
18. LaMontagne MP, Blumbergs P, Strube RE. 1982a. Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents. J Med Chem 25:1094-1097.
19. LaMontagne MP, Markovac A, Khan MS. 1982b. Antimalarials. 13. 5-Alkoxy analogues of 4-methylprimaquine. J Med Chem 25:964-968.
20. Lauer WMRC, Arnold RT, Drake NL, Hook JV, Tinker J. 1946. Some derivatives of 8-aminoquinoline. J Am Chem Soc 68:1546-1548.
21. Levitt ML, Koty PP. 1999. Tyrosine kinase inhibitors in preclinical development. Invest New Drugs 17:213-226.
22. Livny O, Kaplan I, Reifen R, Polak-Charcon S, Madar Z, Schwartz B. 2002. Lycopene inhibits proliferation and enhances gap-junction communication of KB-1 human oral tumor cells. J Nutr 132:3754-3759.
23. Loewenstein WR. 1979. Junctional intercellular communication and the control of growth. Biochim Biophys Acta 560:1-65.
24. Loewenstein WR. 1981. Junctional intercellular communication: the cell-to-cell membrane channel. Physiol Rev 61:829-913.
25. Loewenstein WR, Kanno Y. 1966. Intercellular communication and the control of tissue growth: lack of communication between cancer cells. Nature 209:1248-1249.
26. Makowski L, Caspar DL, Phillips WC, Goodenough DA. 1977. Gap junction structures. II. Analysis of the x-ray diffraction data. J Cell Biol 74:629-645.
27. Martin PE, Evans WH. 2004. Incorporation of connexins into plasma membranes and gap junctions. Cardiovasc Res 62:378-387.
28. Morris GM, Goodsell DS, Huey R, Olson AJ. 1996. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des 10:293-304.
29. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. 1998. Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function. J Comp Chem 19:1639-1662.
30. Musil LS, Le AC, VanSlyke JK, Roberts LM. 2000. Regulation of connexin degradation as a mechanism to increase gap junction assembly and function. J Biol Chem 275:25207-25215.
31. Na HK, Wilson MR, Kang KS, Chang CC, Grunberger D, Trosko JE. 2000. Restoration of gap junctional intercellular communication by caffeic acid phenethyl ester (CAPE) in a ras-transformed rat liver epithelial cell line. Cancer Lett 157:31-38.
32. O'Byrne KJ, Han C, Mitchell K, Lane D, Carmichael J, Harris AL, Talbot DC. 1998. Phase II study of liarozole in advanced non-small cell lung cancer. Eur J Cancer 34:1463-1466.
33. Ruch RJ. 1994. The role of gap junctional intercellular communication in neoplasia. Ann Clin Lab Sci 24:216-212.
34. Ruch RJ, Madhukar BV, Trosko JE, Klaunig JE. 1993. Reversal of ras-induced inhibition of gap-junctional intercellular communication, transformation, and tumorigenesis by lovastatin. Mol Carcinog 7:50-59.
35. Saez CG, Velasquez L, Montoya M, Eugenin E, Alvarez MG. 2003. Increased gap junctional intercellular communication is directly related to the anti-tumor effect of all-trans-retinoic acid plus tamoxifen in a human mammary cancer cell line. J Cell Biochem 89:450-461.
36. Shi A, Nguyen TA, Battina SK, Rana S, Takemoto DJ, Chiang PK, Hua DH. 2008. Synthesis and anti-breast cancer activities of substituted quinolines. Bioorg Med Chem Lett 18:3364-3368.
37. Trosko JE, Chang CC. 2001. Mechanism of up-regulated gap junctional intercellular communication during chemoprevention and chemotherapy of cancer. Mutat Res 480-481:219-229.
38. Trosko JE, Chang CC, Madhukar BV, Klaunig JE. 1990. Chemical, oncogene and growth factor inhibition gap junctional intercellular communication: an integrative hypothesis of carcinogenesis. Pathobiology 58:265-278.
39. Unger VM, Kumar NM, Gilula NB, Yeager M. 1999. Three-dimensional structure of a recombinant gap junction membrane channel. Science 283:1176-1180.
40. Veenstra RD. 2003. gap junction channel structure. Recent Res Dev Biophys 2:65-94.
41. Veyssier P, Bryskier A. 2005. Dihydrofolate reductase inhibitors, nitroheterocycles (furans) and 8-hydroxyquinolines. Antimicrobial Agents. p 941-963.
42. Wei N, Mi MT, Zhou Y. 2007. Influences of lovastatin on membrane ion flow and intracellular signaling in breast cancer cells. Cell Mol Biol Lett 12:1-15.
43. Wiesner J, Ortmann R, Jomaa H, Schlitzer M. 2003. New antimalarial drugs. Angew Chem Int Ed 42:5274-5293.
44. Wilgenbus KK, Kirkpatrick CJ, Knuechel R, Willecke K, Traub O. 1992. Expression of Cx26, Cx32 and Cx43 gap junction proteins in normal and neoplastic human tissues. Int J Cancer 51:522-529.
45. Yamasaki H, Naus CC. 1996. Role of connexin genes in growth control. Carcinogenesis 17:1199-1213.
46. Zhang ZQ, Lin ZX, Lu YY. 1994. Studies on the reduction of malignant phenotypes in a highly metastatic human lung carcinoma-correlated changes of intercellular communication, cytoskeletons, oncogenes and antioncogene. Cancer Res 16:88-92.
47. Zhu D, Kidder GM, Caveney S, Naus CC. 1992. Growth retardation in glioma cells cocultured with cells overexpressing a gap junction protein. Proc Natl Acad Sci USA 89:10218-10221.